DD273285A5 - Verfahren zur Herstellung von Polyeptiden/Proteinen in wesentlichen mit d en Eigenschaften der Vascular-Antikoagulierenden proteinen und deren Verwendung - Google Patents

Verfahren zur Herstellung von Polyeptiden/Proteinen in wesentlichen mit d en Eigenschaften der Vascular-Antikoagulierenden proteinen und deren Verwendung Download PDF

Info

Publication number
DD273285A5
DD273285A5 DD31410688A DD31410688A DD273285A5 DD 273285 A5 DD273285 A5 DD 273285A5 DD 31410688 A DD31410688 A DD 31410688A DD 31410688 A DD31410688 A DD 31410688A DD 273285 A5 DD273285 A5 DD 273285A5
Authority
DD
German Democratic Republic
Prior art keywords
leu
giu
ser
thr
ala
Prior art date
Application number
DD31410688A
Other languages
German (de)
English (en)
Inventor
Rudolf Hauptmann
Ingrid Maurer-Fogy
Gerhard Bodo
Peter Swetly
Christian Stratowa
Edgar Falkner
Guenther Adolf
Christian M P Reutelingsperger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19873710309 external-priority patent/DE3710309A1/de
Priority claimed from DE19873710364 external-priority patent/DE3710364A1/de
Priority claimed from DE19873710430 external-priority patent/DE3710430A1/de
Priority claimed from DE19873737367 external-priority patent/DE3737367A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of DD273285A5 publication Critical patent/DD273285A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
DD31410688A 1987-03-28 1988-03-28 Verfahren zur Herstellung von Polyeptiden/Proteinen in wesentlichen mit d en Eigenschaften der Vascular-Antikoagulierenden proteinen und deren Verwendung DD273285A5 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19873710309 DE3710309A1 (de) 1987-03-28 1987-03-28 Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung
DE19873710364 DE3710364A1 (de) 1987-03-28 1987-03-28 Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung
DE19873710430 DE3710430A1 (de) 1987-03-28 1987-03-28 Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung
DE19873737367 DE3737367A1 (de) 1987-11-04 1987-11-04 Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung

Publications (1)

Publication Number Publication Date
DD273285A5 true DD273285A5 (de) 1989-11-08

Family

ID=27433878

Family Applications (1)

Application Number Title Priority Date Filing Date
DD31410688A DD273285A5 (de) 1987-03-28 1988-03-28 Verfahren zur Herstellung von Polyeptiden/Proteinen in wesentlichen mit d en Eigenschaften der Vascular-Antikoagulierenden proteinen und deren Verwendung

Country Status (17)

Country Link
US (1) US5837842A (fi)
EP (1) EP0293567B1 (fi)
JP (1) JPH01503515A (fi)
KR (1) KR890700666A (fi)
AT (1) ATE133707T1 (fi)
AU (1) AU625214B2 (fi)
DD (1) DD273285A5 (fi)
DE (1) DE3854950D1 (fi)
DK (1) DK175468B1 (fi)
FI (1) FI103892B1 (fi)
HU (1) HUT52544A (fi)
IE (2) IE960853L (fi)
IL (1) IL85878A (fi)
NO (1) NO885275L (fi)
NZ (1) NZ224057A (fi)
PT (1) PT87083B (fi)
WO (1) WO1988007576A2 (fi)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2660514B2 (ja) * 1987-02-20 1997-10-08 興和株式会社 抗血液凝固作用を有するポリペプチド
DE68923107T2 (de) * 1988-02-26 1996-01-18 Biogen Inc DNA-Sequenzen, rekombinante DNA-Moleküle und Verfahren zur Herstellung von Lipocortin III, IV, V, und VI.
AU3231189A (en) * 1988-03-31 1989-10-05 Rorer International (Overseas) Inc. Recombinant endonexin ii
DE3910240A1 (de) * 1989-03-30 1990-10-04 Behringwerke Ag Pp4-delta, seine herstellung und verwendung
ATE89169T1 (de) * 1989-07-15 1993-05-15 Boehringer Ingelheim Int Antikoagulanz enthaltendes mittel.
DE3937607A1 (de) * 1989-11-11 1991-05-16 Boehringer Ingelheim Int Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
HUT61491A (en) * 1989-12-27 1993-01-28 Boehringer Ingelheim Int Process and reagent for diagnosing prothrombic state
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
CA2086437A1 (en) * 1991-05-09 1992-11-10 Jonathan Tait Phospholipid-targeted thrombolytic agents
DK0672136T3 (da) * 1992-07-08 2000-08-21 Innogenetics Nv Polypeptider, der er afledt fra endonexin 2 og har hepatitis B virus-receptoraktivitet, og deres anvendelse i diagnostiske
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
EP0741144B1 (en) * 1994-11-11 2002-07-24 Noboru Kaneko Antiannexin-v monoclonal antibody, process for producing the same, and use therof
EP1379266B1 (en) * 2001-02-21 2007-04-18 SurroMed, Inc. Modified annexin proteins and prevention and treatment of thrombosis
US20050222030A1 (en) * 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
AU784548B2 (en) * 2001-03-16 2006-04-27 Ortho-Clinical Diagnostics, Inc. Reg-like protein
EP1267169B1 (en) * 2001-05-21 2004-12-15 Fuji Photo Film Co., Ltd. Biochemical analysis unit and method for its production
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
FR2841557B1 (fr) * 2002-07-01 2005-12-09 Commissariat Energie Atomique Peptides ayant une affinite pour un phospholipide et utilisations
FR2841558B1 (fr) * 2002-07-01 2004-08-13 Commissariat Energie Atomique Peptides marques ayant une affinite pour un phospholipide et utilisations
EP1533619B1 (en) * 2003-11-20 2009-04-29 F. Hoffmann-Roche AG Specific markers for metabolic syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3438296A1 (de) * 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel
US5066788A (en) * 1984-09-21 1991-11-19 Boehringer Ingelheim International Gmbh Blood coagulation inhibiting proteins, processes for preparing them and their uses
HU199883B (en) * 1984-09-21 1990-03-28 Boehringer Ingelheim Int Process for producing anticoagulant proteins and pharmaceutical compositions comprising same
JPH0787789B2 (ja) * 1985-01-10 1995-09-27 バイオジェン インコーポレイテッド リポコルチンをコードするｄｎａ分子および形質転換宿主
EP0218696A4 (en) * 1985-04-15 1989-08-16 Biotech Res Partners Ltd ANTI-INFLAMMATORY PROTEIN FOR INHIBITION OF HUMAN PHOSPHOLIPASE.
CA1265446A (en) * 1985-09-30 1990-02-06 Masahiro Maki Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
WO1988005659A1 (en) * 1987-02-06 1988-08-11 Zymogenetics, Inc. Human proteins having anticoagulant and anti-inflammatory activity
US4937324A (en) * 1987-02-06 1990-06-26 Zymogenetics, Inc. Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
US5179081A (en) * 1988-07-21 1993-01-12 Kowa Co., Ltd. Method of treatment using an anticoagulant polypeptide

Also Published As

Publication number Publication date
FI103892B (fi) 1999-10-15
FI103892B1 (fi) 1999-10-15
IE880928L (en) 1988-09-28
DK662288D0 (da) 1988-11-25
AU1402788A (en) 1988-09-29
EP0293567B1 (de) 1996-01-31
FI885504A (fi) 1988-11-28
JPH01503515A (ja) 1989-11-30
NO885275L (no) 1989-01-25
AU625214B2 (en) 1992-07-02
WO1988007576A3 (fr) 1989-01-26
NO885275D0 (no) 1988-11-25
US5837842A (en) 1998-11-17
IL85878A (en) 1993-07-08
IL85878A0 (en) 1988-09-30
PT87083B (pt) 1992-07-31
WO1988007576A2 (fr) 1988-10-06
FI885504A0 (fi) 1988-11-28
DE3854950D1 (de) 1996-03-14
DK175468B1 (da) 2004-11-01
IE960853L (en) 1988-09-28
ATE133707T1 (de) 1996-02-15
NZ224057A (en) 1991-04-26
IE74679B1 (en) 1997-07-30
PT87083A (pt) 1988-04-01
KR890700666A (ko) 1989-11-26
DK662288A (da) 1989-01-25
EP0293567A1 (de) 1988-12-07
HUT52544A (en) 1990-07-28

Similar Documents

Publication Publication Date Title
DD273285A5 (de) Verfahren zur Herstellung von Polyeptiden/Proteinen in wesentlichen mit d en Eigenschaften der Vascular-Antikoagulierenden proteinen und deren Verwendung
DE3650267T3 (de) Die alpha- oder beta-Ketten von Inhibin codierende Nukleinsäure und Verfahren zur Synthese von Polypeptiden unter Verwendung einer solchen Nukleinsäure.
DE68910354T2 (de) Menschliches mutantes Angiogenin (Angiogenese-Faktor mit überlegener Angiogenin-Aktivität), Gene dafür und Methode zur Expression.
DE69018920T2 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
EP0168342B1 (de) Verfahren zur Herstellung von Thrombin-Inhibitoren
DE69024104T2 (de) Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase
EP0769020B1 (de) NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
DD296965A5 (de) Hefeverarbeitungssystem
US5296467A (en) Composition comprising an anticoagulant
DE3787820T2 (de) Für Flagellin kodierende DNS und dieses enthaltender Vektor.
CH681080A5 (fi)
DE3686399T2 (de) Herstellung von thrombin-inhibitoren.
DE3752008T2 (de) Hybride Plasminogenaktivatoren
DE3600571A1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel
DE3750379T3 (de) Varianten des abbaubeschleunigenden Faktors (DAF), hergestellt durch rekombinante DNS-Technologie.
DE3687948T2 (de) Verfahren und nukleinsaeure zur herstellung von lecithin: cholestrinacyltransferase.
DE3751081T2 (de) [Leu 13] Motilin, dessen kodierende DNS-Moleküle und Verfahren zu dessen Herstellung.
EP0677107B1 (de) Thrombininhibitor aus speichel von protostomiern
DE3724581A1 (de) Dna-sequenzen, die fuer proteine mit den biologischen eigenschaften des cystatin c codieren, herstellung dieser dna-sequenzen, expression des cystatin c sowie dieses enthaltende pharmazeutische zubereitungen
DD284045A5 (de) Verfahren zur herstellung von desulfarohirudinmutanten
EP0244627A2 (de) Expressionsvektoren zur Gewinnung von Polypeptiden
DE3786870T2 (de) Methode zur Herstellung von Proteinen.
WO2002004486A2 (de) Bifunktionale fusionsproteine aus hirudin und tap
DE69106498T2 (de) Stamm ral-4, nützlich zur herstellung kleiner proteine und peptide.
DE3737367A1 (de) Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee